Please assess the completion status of the following clinical trial:

Trial Title: PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Refer to the master protocol (NCT04501978)~Exclusion Criteria: Refer to the master protocol (NCT04501978)~Additional Exclusion Criteria:~1. Participants with moderate to severe hepatic impairment (i.e. Child-Pugh class B or C) or acute liver failure.~2. Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 (see Section H6.3.4).~3. Patients will be excluded if taking drugs which have a narrow therapeutic window that are substrates of CYP3A4, including but not limited to: astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus, and terfenadine.~4. Pregnant women~5. Nursing mothers~6. Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 5 weeks of the study.~7. Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 5 weeks of the study.~8. Patients with a history of deep vein thrombosis or pulmonary thrombotic embolism\*.~   * Prior to the initial futility assessment, which is performed when approximately 150 patients have been enrolled on PF-07304814 and 150 on placebo, patients with a history of deep vein thrombosis or pulmonary embolism will be excluded. These patients will be eligible for the trial if the initial futility assessment is passed by this agent, and if risk-benefit is favorable based on an assessment of available data that is reviewed by the independent DSMB. These data will include treatment comparisons of thromboembolic events and coagulation markers, and any additional data from studies carried out by Pfizer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07304814 plus SOC (Type: EXPERIMENTAL): * PF-07304814 250 mg per day for 5 days; administered as a constant rate IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion
- Placebo plus SOC (Type: PLACEBO_COMPARATOR): * Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).